Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Siddesh V Hartimath

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Molecular Pharmaceutics|January 4, 2019
<sup>111</sup>In-Labeled Glycoprotein Nonmetastatic b (GPNMB) Targeted Gemini Surfactant-Based Nanoparticles against Melanoma: In Vitro Characterization and in Vivo Evaluation in Melanoma Mouse Xenograft ModelAmal Makhlouf, Istvan Hajdu, Siddesh V Hartimath, et al.
European Journal of Medicinal Chemistry|August 14, 2018
<sup>99m</sup>Tc(CO)<sub>3</sub><sup>+</sup> labeled domain I/II-specific anti-EGFR (scFv)<sub>2</sub> antibody fragment for imaging EGFR expressionViswas Raja Solomon, Carolina Gonzalez, Elahe Alizadeh, et al.
Nuclear Medicine and Biology|March 26, 2013
[⁹⁹mTc]O₂-AMD3100 as a SPECT tracer for CXCR4 receptor imagingSiddesh V Hartimath, Urszula M Domanska, Annemiek M E Walenkamp, et al.
Molecular Pharmaceutics|September 14, 2019
<sup>111</sup>In- and <sup>225</sup>Ac-Labeled Cixutumumab for Imaging and α-Particle Radiotherapy of IGF-1R Positive Triple-Negative Breast CancerViswas Raja Solomon, Elahe Alizadeh, Wendy Bernhard, et al.
Molecules (Basel, Switzerland)|April 3, 2021
An Improved Synthesis of N-(4-[<sup>18</sup>F]Fluorobenzoyl)-Interleukin-2 for the Preclinical PET Imaging of Tumour-Infiltrating T-cells in CT26 and MC38 Colon Cancer ModelsShivashankar Khanapur, Fui Fong Yong, Siddesh V Hartimath, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 29, 2024
Novel [<sup>18</sup>F]FPG-interleukin-2 conjugate for monitoring immune checkpoint therapy with positron emission tomographyPragalath Sadasivam, Siddesh V Hartimath, Shivashankar Khanapur, et al.
Biomedicines|October 27, 2022
Imaging Effector Memory T-Cells Predicts Response to PD1-Chemotherapy Combinations in Colon CancerJulian L Goggi, Shivashankar Khanapur, Siddesh V Hartimath, et al.
Oncotarget|February 26, 2019
Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograftSiddesh V Hartimath, Ayman El-Sayed, Amal Makhlouf, et al.
Scientific Reports|October 30, 2020
Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancerViswas Raja Solomon, Elahe Alizadeh, Wendy Bernhard, et al.
Pharmaceutics|January 21, 2022
Granzyme B PET Imaging in Response to In Situ Vaccine Therapy Combined with αPD1 in a Murine Colon Cancer ModelSiddesh V Hartimath, Boominathan Ramasamy, Tan Yun Xuan, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Molecular Pharmaceutics|January 4, 2019
<sup>111</sup>In-Labeled Glycoprotein Nonmetastatic b (GPNMB) Targeted Gemini Surfactant-Based Nanoparticles against Melanoma: In Vitro Characterization and in Vivo Evaluation in Melanoma Mouse Xenograft ModelAmal Makhlouf, Istvan Hajdu, Siddesh V Hartimath, et al.
European Journal of Medicinal Chemistry|August 14, 2018
<sup>99m</sup>Tc(CO)<sub>3</sub><sup>+</sup> labeled domain I/II-specific anti-EGFR (scFv)<sub>2</sub> antibody fragment for imaging EGFR expressionViswas Raja Solomon, Carolina Gonzalez, Elahe Alizadeh, et al.
Nuclear Medicine and Biology|March 26, 2013
[⁹⁹mTc]O₂-AMD3100 as a SPECT tracer for CXCR4 receptor imagingSiddesh V Hartimath, Urszula M Domanska, Annemiek M E Walenkamp, et al.
Molecular Pharmaceutics|September 14, 2019
<sup>111</sup>In- and <sup>225</sup>Ac-Labeled Cixutumumab for Imaging and α-Particle Radiotherapy of IGF-1R Positive Triple-Negative Breast CancerViswas Raja Solomon, Elahe Alizadeh, Wendy Bernhard, et al.
Molecules (Basel, Switzerland)|April 3, 2021
An Improved Synthesis of N-(4-[<sup>18</sup>F]Fluorobenzoyl)-Interleukin-2 for the Preclinical PET Imaging of Tumour-Infiltrating T-cells in CT26 and MC38 Colon Cancer ModelsShivashankar Khanapur, Fui Fong Yong, Siddesh V Hartimath, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 29, 2024
Novel [<sup>18</sup>F]FPG-interleukin-2 conjugate for monitoring immune checkpoint therapy with positron emission tomographyPragalath Sadasivam, Siddesh V Hartimath, Shivashankar Khanapur, et al.
Biomedicines|October 27, 2022
Imaging Effector Memory T-Cells Predicts Response to PD1-Chemotherapy Combinations in Colon CancerJulian L Goggi, Shivashankar Khanapur, Siddesh V Hartimath, et al.
Oncotarget|February 26, 2019
Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograftSiddesh V Hartimath, Ayman El-Sayed, Amal Makhlouf, et al.
Scientific Reports|October 30, 2020
Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancerViswas Raja Solomon, Elahe Alizadeh, Wendy Bernhard, et al.
Pharmaceutics|January 21, 2022
Granzyme B PET Imaging in Response to In Situ Vaccine Therapy Combined with αPD1 in a Murine Colon Cancer ModelSiddesh V Hartimath, Boominathan Ramasamy, Tan Yun Xuan, et al.
Pageof 3